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Abstract. Non-Hodgkin’s lymphoma comprises many related but distinct diseases and diagnosis and classification is complex.
Protein profiling of lymphoma biopsies may be of potential value for use in this lymphoma classification and the discovery of
novel markers. In this study, we have optimized a method for SELDI-TOF MS based protein profiling of frozen tissue sections,
without dissection of tumour cells. First we have compared chip surfaces and lysis buffers. Also, we have determined the minimal
input using laser dissection microscopy. Subsequently, we have analyzed and compared protein profiles of diffuse large B-cell
lymphoma (n = 8), follicular lymphoma (n = 8) and mantle cell lymphoma (n = 8). Benign, reactive lymph nodes (n = 14)
were used as a reference group.
CM10 chip surface in combination with urea lysis buffer and an input of approximately 50,000 lymphocytes allowed the de-
tection of many differential peaks. Identification of the diffuse large B-cell lymphoma cases was reliably made in the supervised
classification. Unsupervised clustering showed segregation into a benign/indolent cluster predominantly formed by benign, reac-
tive lymph nodes and follicular lymphoma cases and into a more aggressive cluster formed by diffuse large B-cell lymphoma and
mantle cell lymphoma cases. In conclusion, our protocol enables protein profiling of protein lysates derived from small histolog-
ical samples and the subsequent detection of many differentially expressed proteins, without the need of tumour cell dissection.
These results support further evaluation of protein profiling of small lymphoma biopsies as an additional tool in pathology.
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Abbreviations
B-NHL: B-cell non-Hodgkin’s lymphoma,
DLBCL: diffuse large B-cell lymphoma,
FL: follicular lymphoma,
LDM: laser dissection microscopy,
MCL: mantle cell lymphoma,
SELDI-TOF MS: surface enhanced laser dissec-
tion/ionization time-of-flight
mass spectrometry.
1. Introduction
Non-Hodgkin’s lymphoma (NHL) diagnosis is
based on classification according to the World Health
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Organization Classification [1] by integrating mor-
phological, immunochemical and molecular features.
Pathological diagnosis is primarily based on the use
of tissue biopsies. For classification of the different B-
and T-cell entities, immunohistochemistry using anti-
bodies against marker proteins is an important supple-
mentary technique. The continuous recognition of new
clinical and biological disease entities requires a grow-
ing arsenal of techniques for classification and detec-
tion of new prognostic and therapeutic markers. The
use of mass spectrometry based techniques for protein
profiling of diagnostic tissue samples is expected to
meet these requirements as it enables the simultaneous
analysis of many different proteins.
Protein profiling techniques that require relatively
low amounts of diagnostic input material are liq-
uid chromatography-MS/MS, which has successfully
been applied in human anaplastic large cell lym-
phoma [2,3] and in follicular lymphoma-derived cells
1570-5870/08/$17.00© 2008 – IOS Press and the authors. All rights reserved
28 C. Jansen et al. / Protein profiling of histological samples
[4], and ProteinChipTM technology. The last technol-
ogy is based on an application of mass spectrometry
called Surface Enhanced Laser Desorption/Ionization-
Time of Flight Mass Spectrometry (SELDI-TOF MS)
that enables simultaneous on-chip binding and high
throughput analysis of small, complex diagnostic pro-
tein samples. SELDI-TOF MS based protein profiling
has successfully been applied for the discrimination
between normal and disease in serum samples [5–11],
whole tissues [12], and laser dissected tissues [13,14].
SELDI-TOF MS also assisted in the discovery of po-
tentially new biomarkers in different carcinomas [15–
18].
In the present study we have optimized the SELDI-
TOF MS application for diagnostic frozen tissue sec-
tions of different categories of malignant lymphoma.
This was done by comparing two different chip types
in combination with two different lyses buffers. To as-
sess the clinical applicability of the method for small
samples like i.e. core needle biopsies or cytological
specimens, the minimal amount of input material re-
quired for SELDI-TOF MS was evaluated. In addi-
tion, we have evaluated this optimized SELDI-TOF
MS method using complex protein samples prepared
from undissected frozen histological specimens to see
if this method actually enables detection of differential
proteins that enable lymphoma classification. For this
purpose, we focused on the discrimination of benign
lymph nodes from three different malignant B-cell
lymphoma types. A recent paper by Fan et al. [19] de-
scribes the successful differentiation by protein profil-
ing of low grade follicular lymphoma (FL) from the
rare but aggressive Burkitt lymphoma and reactive fol-
licular hyperplasia. For clinical application, compari-
son of the more common lymphomas such as diffuse
large B-cell lymphoma (DLBCL) that constitute 30–
40% of all lymphoma’s is relevant as well. Lin et al.
studied matched pairs of FL and DLBCL counterparts
from two patients and demonstrated the detection of
differentially expressed proteins like cyclin D3 and
caspase3 [20].
Our study includes three common lymphoma types
that are characterized by a different phenotype, mole-
cular background, clinical behaviour and outcome. FL
represents a lymphoma with indolent clinical behav-
iour. DLBCL is the most common group of lym-
phoma with a histological intermediate behaviour,
although clinically heterogeneous. Mantle cell lym-
phoma (MCL) is a more rare disease and has an ad-
verse clinical course. The group of benign lymph nodes
in our study includes reactive follicular hyperplasia,
T-cell hyperplasia and sinus histiocytosis, thereby rep-
resenting a large part of the spectrum of benign nodes
that are seen in a routine diagnostic setting. We have
analyzed protein lysates prepared from frozen tissue of
archival, routinely diagnosed cases. Our study shows
the potential value of protein profiling.
2. Materials and methods
2.1. Samples included in the classification study
Diagnostic frozen tissue samples were obtained
from the archive of the Department of Pathology, Rad-
boud University Nijmegen Medical Centre, Nijmegen,
the Netherlands. Samples were obtained according to
the Code Proper Secondary Use of Human Tissue
[21]. All NHL samples were classified according to
the World Health Organization Classification [1]. For
this study we used lymph node biopsies containing
DLBCL (n = 8), FL (n = 8) (FL cases 2 and 5 are of
grade I and the six other FL cases are of grade III) and
MCL (n = 8). Tumour load varied, ranging from 50–
90%. Benign lymph nodes (RL, n = 14) were used as
a reference group and these cases harboured different
amounts of common hyperplasia types.
2.2. Chip information and sample preparation
In order to optimise the protocol for profiling of tis-
sue lysates, the CM10 (cationic exchange) and the Q10
(anionic exchange) chip surfaces were compared to-
gether with two different lysis buffers: an UTC lysis
buffer (6 M Urea, 2 M thio-urea, 2% (w/v) Chaps, 1%
(w/v) DTT, Protease Inhibitor Cocktail (Roche Diag-
nostics, Mannheim, Germany)) and an Imidazole lysis
buffer (10 mM, pH 7).
For sample preparation, approximately 200 mm2
of 10 µm thick frozen tissue sections was obtained
from each case. These sections were homogenized in
100 µl lysis buffer per 100 mm2. Samples were drawn
through an 0.8 mm needle, incubated for one hour at
room temperature, and centrifuged (13,000g, 10 min
at room temperature) to remove cell debris. Protein
concentrations were quantified with the 2D-Quant Kit
(Amersham Biosciences, San Francisco). All concen-
trations were adjusted to 400 ng/µl and 10 µl aliquots
were stored at −80◦C. Adjacent frozen tissue sections
(4 µm) were Hematoxylin and Eosin stained to pro-
vide information on tumour load or, in case of the
benign lymph nodes, on hyperplasia. Technical dupli-
cates were randomized over the chips.
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2.3. Chip loading
Protein samples were analyzed in duplicate on
CM10 and Q10 ProteinChipsTM (Ciphergen Biosys-
tems, Fremont, California). A control sample was used
to determine the %CV values. Before chip loading,
90 µl Acetate binding buffer (0.1 M ammonium ac-
etate, pH 4.5, 0.1% Triton X-100) was added to each
10 µl sample aliquot (containing 4 µg protein) for the
CM10 chips. For the Q10 chips, 90 µl of Tris bind-
ing buffer (0.1 M Tris-HCl, pH 8.0) was added to
each sample. To remove counter ions, the chips were
bulk washed briefly in 10 mM HCl. After placing the
chips into the Bioprocessor (Ciphergen Biosystems),
spots were washed twice with 200 µl binding buffer
for 5 minutes at 600 RPM at room temperature, incu-
bated at 600 RPM for 45 minutes at room temperature,
washed twice with binding buffer to remove unbound
proteins, and twice with chip type specific washing
buffer (chip type specific binding buffer without Tri-
ton X-100) in order to remove traces of Triton X-100;
all washing steps were performed during 5 minutes at
600 RPM at room temperature. After a brief wash with
5 mM HEPES, pH 7.0, chips were removed from the
Bioprocessor and left to dry during 15 minutes. A satu-
rated solution of the energy absorbing molecule sinap-
inic acid, prepared in 50% (v/v) acetonitrile and 0.5%
(v/v) trifluoroacetic acid was applied to each spot twice
(2×1 µl). In order to obtain good crystallization of the
proteins bound to the chip, spots were left to dry for
5 minutes after each SPA application.
2.4. Generating mass spectra
The PBS IIc mass spectrometer (Ciphergen Biosys-
tems), supplemented with an autoloader, was used
to generate Time of Flight (TOF) mass spectra in
the range 0–50,000 Da using Protein Chip Software
(Ciphergen Biosystems). Spectra were obtained with
the following instrument settings: laser energy low
170/high 190, deflector mode set at 1,000 Da, opti-
mization range was set at 3,000–20,000 Da (focus by
optimization centre). Measurements within a spot were
performed from position 20–80, with delta 2, collect-
ing 50 transients per position, and hard shots (at laser
energy 190) were excluded from the averaged data.
Protein Standard (Ciphergen Biosystems) was used for
external calibration and measured at identical instru-
ment settings as the samples. All spectra were pre-
processed using Protein Chip Software. The spectra
were base-line subtracted and noise detection was set
from 2,000 Da up to 50,000 Da without smoothing and
with a fitting width of eight times the expected peak
width.
2.5. Minimal input determination and hyperplasia
comparison using laser dissection microscopy
SELDI-TOF MS has successfully been applied for
protein profiling of small numbers of epithelial cells
in the context of carcinoma. As B-lymphocytes con-
tain less cytoplasm than epithelial cells, we have de-
termined the minimal input of lymphoid tissue. The
minimal number of cells necessary for profiling was
assessed by analyzing lysates prepared from differ-
ent numbers of germinal centre B-cells. Independent
samples, containing approximately 48,000, 24,000,
12,000, 6,000, 3,000, and 1,500 germinal centre cells
were collected from hematoxylin stained benign lymph
node sections with follicular hyperplasia using laser
dissection with a Leica AS LDM microdissection sys-
tem with a UV laser (Leica Microsystems Wetzlar
GmbH, Germany). The dissected cells were subse-
quently homogenized in 12 µl UTC lysis buffer and
stored at −80◦C. The protein concentration of a pro-
tein lysate of approximately 50,000 cells was quanti-
fied with the 2D-Quant Kit. All samples were loaded
on CM10 chips and analyzed as described above.
For a few additional reactive lymph node cases, dif-
ferent hyperplastic areas were dissected and used for
comparison of their protein profiles. These hyperplasia
types were follicular hyperplasia that mainly consists
of B-cells, paracortical hyperplasia which predomi-
nantly contains T-cells, and sinus histiocytosis that
shows an increase of fibrosis, sinus expansion and si-
nus histiocytes. For each hyperplasia type, comparable
areas (corresponding to approximately 50,000 B-cells)
were obtained with laser micro dissection from hema-
toxylin stained frozen tissue sections and processed as
described above.
2.6. Data analysis
Samples were analyzed on different days. In or-
der to correct for inter-experiment variation, spectra
with comparable averaged total ion currents (AveTIC)
and protein profiles were included in the analysis. Se-
lected spectra were exported to CiphergenExpressTM,
mass aligned and normalization was performed from
2,000 Da up to 50,000 Da using an external normal-
ization coefficient of 0.2. Cluster detection was per-
formed with signal-to-noise threshold for the first pass
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peak detection at 8.0, and peaks should be present in
at least 12% of all spectra. For the second pass peak
detection, a signal-to-noise threshold at 2.0 was used
and estimated peaks were included. Generated peak
clusters were analyzed (CiphergenExpressTM) to de-
tect differentially expressed protein peaks. In addition
to this supervised approach, data were analyzed using
unsupervised hierarchical clustering.
3. Results
3.1. Optimizing SELDI-TOF MS application for
lymphoma tissue samples
To select a method that would give sufficient peaks
to enable protein profiling, we have tested two differ-
ent lysis buffers and different chip surfaces, a cationic
(CM10) and an anionic (Q10) chip surface. Spec-
tra generated on the Q10 chips showed relatively
few peaks for both buffers in the range of 6,000–
16,000 M/Z (Fig. 1C and D: 9,000–16,000 M/Z).
The combination of CM10 chip and Urea/UTC buffer
(Fig. 1A) resulted in detection of the highest number
of peaks; 94 unique peaks with a signal/noise 2. Be-
cause the presence of many peaks makes detection of
differential protein present in the different lymphoma
subtypes more likely, the last combination was used for
further experiments.
In order to determine the minimal input for profil-
ing, protein lysates were generated from different num-
bers of laser dissected germinal centre cells that were
stained with Hematoxylin. The Hematoxylin stain-
ing of the sections prior to dissection did not inter-
fere with the SELDI-TOF MS procedure (data not
shown). Highly similar mass spectra were obtained
Fig. 1. Comparison of different chip surfaces and lysis buffers for the generation of protein profiles from frozen tissue sections. Frozen tissue
sections from a benign reactive lymph node were homogenized in Urea lysis buffer and Imidazole lysis buffer. Equal amounts of protein were
loaded onto CM10 and Q10 chips. The upper panel shows a segment of the resulting mass spectra in the range of 9,000–16,000 M/Z (X-axis).
The relative peak intensities are plotted along the Y -axis. The combination of the Urea lysis buffer and CM10 chip surface allows detection of
more proteins as compared to the other combinations tested. In the lower panel, the spectra from the upper panel are visualized as gel traces (gel
view).
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Fig. 2. Determination of the minimal input of B-cells for SELDI-TOF MS based protein profiling. Mass spectra were generated from different
numbers of laser dissected germinal centre B-cells: 48,000, 24,000, 12,000, 6,000, 3,000 and 1,500 cells (Fig. 2A–F, respectively). For all
spectra generated, the segment from 7,500–15,000 M/Z is shown. Prior to analysis, a lysate of approximately 48,000 laser dissected B-cells was
quantified and corresponded to 4 ug of whole protein.
from 48,000 and 24,000 germinal centre cells (Fig. 2).
Lower cell numbers showed a major decrease in peak
intensities. We therefore decided to use 48,000 cells,
where 48,000 B-cells correspond to 4 ug of whole pro-
tein. This amount corresponds to approximately 3 mm2
of a 10 um frozen tissue section and illustrates the
small size of this sample.
3.2. Protein profiling of B-cell non-Hodgkin’s
lymphoma
We have analyzed protein lysates from frozen tis-
sue sections of cases of DLBCL (n = 8), FL (n = 8)
and MCL (n = 8). The group of benign lymph nodes
consisted of different types of RL (n = 14). To as-
sess intra-experiment and inter-experiment variation,
we have analysed fifteen replicate samples on two dif-
ferent days. Please note that all these thirty spots were
each on a different chip. The pooled relative variation
(%CVp) values for intra-experimental variation of the
ion intensities for day 1 and day 2 were 31.5% and
34.8%, respectively. The inter-experiment %CVp re-
sulting from these experiments is 35.4%. These values
are comparable to previous reports [22,23].
In this study, ninety-four clusters were detected us-
ing the criteria described in Section 2.6. P -values
should be <0.00053 (0.05/94) to be significant (Bon-
ferroni correction for multiple testing). We detected
multiple peaks that differentiated between the differ-
ent lymphoma types. One example is a peak at M/Z
5,567, which significantly differentiates DLBCL from
the other lymphoma types and the RL (Kruskal–Wallis
H test, p-value= 0.00002) (Fig. 3A, D). An additional
classifier peak at M/Z = 2,384 is applicable for further
differentiation between benign lymph node cases and
the cases of FL and MCL (Kruskal–Wallis H test, p-
value= 0.0002) (Fig. 3B, E). A third example of a dif-
ferentially expressed peak is at M/Z = 15,106 that dis-
criminates between MCL and FL cases, however not
significantly (Mann–Whitney U test, p-value = 0.12)
(Fig. 3C, F).
Although the case numbers are relatively limited,
a supervised classification algorithm was constructed
based on the differentially expressed peaks detected.
The algorithm was internally validated using 8-fold
cross validation resulting in the development of the
most optimal classification tree. The resulting algo-
rithm (Fig. 4) combines three peaks to classify the lym-
phoma cases and discriminate them from the benign
lesions. The predicted classification success was 75%
for follicular lymphoma and 87.5% for diffuse large
B-cell lymphoma; for mantle cell lymphoma the pre-
dicted success was 37.5% (Table 1A and B).
We also performed unsupervised clustering for the
detected peak-clusters (Fig. 5). This approach uses all
clusters (peaks) to evaluate which cases are most sim-
32 C. Jansen et al. / Protein profiling of histological samples
Fig. 3. SELDI-TOF MS enables detection of differentially expressed proteins in lymphoma tissue samples. Examples of three differentially
expressed peaks are shown in panels A–C. A small peak at M/Z 5,567 is detected in reactive benign nodes, FL and MCL but is absent in cases
of DLBCL (p–value < 0.00002) (Fig. 3A). Similarly, a peak at M/Z 2,384 is expressed in benign reactive nodes, but this peak is almost absent
in the spectra of MCL and FL cases (p-value < 0.0002) (Fig. 3B). A third example of a peak at M/Z 15,106 shows a differential expression,
however the difference is not significant (p-value= 0.12) (Fig. 3C). The lower panels (Fig. 3D–E) show the corresponding box-whisker plots for
the mean intensities (Y-axis) of the peaks at M/Z 5,567, 2,384 and 15,106 respectively. The different groups are plotted along the X-axis.
ilar. A large cluster of predominantly RL nodes and
FL cases was formed on the right and a cluster of pre-
dominantly DLBCL and MCL cases was formed on the
left (groups are indicated with coloured lines). How-
ever, this clustering is not entirely according the patho-
logical classification. It is important to realise though
that there may be many sample characteristics reflected
at the protein level and thus in the protein profiles,
thereby possibly influencing the unsupervised cluster-
ing. This is probably observed for several cases of the
FL group that cluster next to the benign cases. These
FL cases harbour many T-cells and dendritic cells, as
do the benign cases and may explain why they are
clustered together. In contrary, DLBCL case 11 and 12
have a relatively low tumour load of 50% and this may
account for their clustering separately from the other
DLBCL with higher tumour loads (Table 3). Further-
more, MCL and DLBCL are both regarded as interme-
diate aggressive lymphoma and their joint clustering in
two neighbouring branches may be reflecting this clin-
ical behaviour in some way. Unsupervised clustering
of the fourteen benign, reactive lymph node cases as
a separate group showed no evident clustering based
on hyperplasia type (Fig. 6). The composition of these
reactive lymph nodes regarding the amount and com-
bination of hyperplasia types was assessed using H&E
stained tissue sections adjacent to the sections used for
LDM (Table 2). Also, protein profiles generated from
laser micro dissected hyperplasia types showed many
similarities (Fig. 7).
4. Discussion
In this study we have optimized a protocol for
SELDI-TOF MS based protein profiling of small lym-
phoma tissue samples that allowed detection of many
unique peaks. With the set criteria (Section 2.6),
ninety-four unique peaks were detected of which many
were differentially expressed.
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Table 1
Classification results for the supervised classification algorithm. The actual classification results for the generated supervised algorithm are
shown (Table 1A) together with the predicted classification results (Table 1B), obtained after V-fold cross validation
Predicted class
Actual Total Percent DLBCL FL MCL Benign
class cases correct n = 8 n = 8 n = 8 n = 8
DLBCL 8 100 8 0 0 0
FL 8 100 0 8 0 0
MCL 8 75 0 2 6 0
Benign 14 86 0 2 0 12
A: actual classification result.
Predicted class
Actual Total Percent DLBCL FL MCL Benign
class cases correct n = 8 n = 8 n = 8 n = 8
DLBCL 8 87.5 7 0 0 1
FL 8 75.0 0 6 2 0
MCL 8 37.5 0 5 3 0
Benign 14 85.7 0 2 0 12
B: predicted classification after V-fold cross-validation.
Fig. 4. SELDI-TOF MS based supervised classification algorithm for
the classification of DLBCL, FL, MCL and benign lymph nodes. The
algorithm is illustrated as a decision-tree with three splits or classi-
fier peaks. The classifier peaks are given by their M/Z values in com-
bination with the intensity (int) threshold used for classification. The
underlined sample group is the one that predominates the resulting
group after classification; the number of cases present of each group
is indicated between brackets.
Using laser dissection microscopy, we have deter-
mined that only very small parts of frozen tissue biop-
sies, corresponding to about 3 mm2 of 10 µm frozen
tissue section or approximately 50,000 cells, are al-
ready sufficient to generate SELDI-TOF mass spectra.
The dissected samples were independently collected
and are therefore not identical, resulting in some very
subtle differences between the spectra of 24,000 and
48,000 cells. Cell numbers ranging between 500–5,000
cells per sample have been reported in SELDI-TOF
MS studies before [15,24]. However, these studies used
epithelial cells that are much larger and contain more
proteins than the B- and T-cells from the lymphoma
specimens used in this study. The small size of the tis-
sue sections required for analysis allows the use of this
technique when limited diagnostic material is available
in case of, for example, core needle biopsies or fine
needle aspirates of tissues suspect for lymphoma.
With our specific protocol for tissue samples we
showed that differentially expressed peaks between
benign nodes, DLBCL and small B-cell lymphoma
subtypes (including FL and MCL) were detected by
SELDI-TOF MS. These differentially expressed peaks
have been used for the generation of a supervised
classification algorithm. Because supervised classifi-
cation is prone to over fitting we applied internal V-
fold cross validation for the generation of the algo-
rithm. The resulting estimations of classification er-
rors give insight into the predicted classification suc-
cess of the algorithm. With our specific protocol for
tissue samples we showed that DLBCL can be reli-
ably identified. Univariate differentiation of MCL and
FL was not significant in this study. The unsupervised
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Fig. 5. Unsupervised clustering of SELDI-TOF MS data of reactive lymph nodes, DLBCL, FL and MCL. Along the X-axis are the lymphoma
cases (each case in duplicate) (MC =MCL; DLB = DLBCL; RL = benign lymph node) and along the Y -axis are the M/Z values of the peaks
that were generated in these spectra and these peaks are all used in this unsupervised clustering. On the right, a cluster of benign, reactive lymph
nodes (red bar) and FL cases (yellow bar) is formed, and on the left DLBCL (blue bar) and MCL (green bar) cases cluster together.
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Table 2
Hyperplasia composition of RL cases in the classification study. Case
replicates are listed in the table according to their order in the unsu-
pervised clustering with the first case in the list corresponding to the
most left one in the image (Fig. 6). The hyperplasia composition was
assessed on the adjacent H&E stained sections, and was expressed
as the relative area of the whole section
Cluster
order
Sample
name
Hyperplasia type (% area)
% area B-cell % area T-cell % area sinus
1 RL11 40 50 10
2 RL11 40 50 10
3 RL08 50 45 5
4 RL08 50 45 5
5 RL24 75 15 10
6 RL31 70 25 5
7 RL24 75 15 10
8 RL31 70 25 5
9 RL02 45 10 45
10 RL05 0 95 5
11 RL05 0 95 5
12 RL21 80 10 10
13 RL21 80 10 10
14 RL26 15 75 10
15 RL25 0 90 10
16 RL25 0 90 10
17 RL28 0 50 50
18 RL26 15 75 10
19 RL06 80 15 5
20 RL06 80 15 5
21 RL02 45 10 45
22 RL28 0 50 50
23 RL29 20 75 5
24 RL29 20 75 5
25 RL30 40 50 10
26 RL30 40 50 10
27 RL18 70 20 10
28 RL18 70 20 10
clustering showed apparent grouping according to, on
the right hand side, a benign/indolent profile and, on
the left hand side, a more aggressive clinical behav-
iour. This also suggests that the generated protein pro-
files contain potentially clinically relevant information.
Identification of discriminating proteins from both the
unsupervised and the supervised analysis is an impor-
tant next step, not only to provide insight into the na-
ture of these proteins, but also for subsequent vali-
dation, and possible application of classifier proteins
as new biomarkers in immunohistochemistry or cyto-
chemistry. As shown in Fig. 6, hyperplasia type does
Table 3
Tumour load of NHL cases in the proteomics study. The tumour
load was assessed using adjacent H&E stained sections, and was ex-
pressed as the relative area of the whole section
Sample Tumour load Grade
(% area)
FL01 60 IIIa
FL02 85 I
FL03 60 IIIa
FL04 75 IIIa
FL05 50 I
FL06 70 IIIa
FL07 60 IIIa
FL08 80 IIIa
MC15 75
MC24 65
MC25 >90
MC29 90
MC37 90
MC43 90
MC52 90
MC68 >90
DLB01 80
DLB02 80
DLB07 90
DLB10 90
DLB11 50
DLB12 50
DLB20 90
DLB33 90
not direct the unsupervised clustering of this hetero-
geneous group of benign, reactive lymph nodes. Ap-
parently, other factors than merely phenotype related
ones, drive their clustering. This is an important ob-
servation because this implies that protein profiling
based classification of benign and malignant lymph
nodes would not be complicated by this heterogene-
ity.
Samples in our study were obtained from whole tis-
sue sections without dissection of tumour cells, de-
spite the fact that lymph nodes and lymphomas are
heterogeneous in cell and stroma composition. The rel-
evance of stroma and micro-environment for tumour
biology and classification is increasingly recognized
[25,26]. Because of this, we have intentionally in-
cluded the micro-environment of the tumour, in con-
trast to earlier tissue profiling studies that have selected
tumour cells by LDM prior to protein profiling [27,
28]. The studied subcategories of B-NHL each have
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Fig. 6. Unsupervised classification of the reactive lymph node cases that contain different combinations and amounts of B-cells, T-cells and sinus
histiocytosis. Along the Y-axis are the benign lymph node cases (each case in duplicate) (RL = benign lymph node). Behind the sample name is
indicated which hyperplasia type and thus which cell type is predominantly present in the sample (B: B-cells or follicular hyperplasia, T: T-cells
or paracortical hyperplasia, and S: sinus histiocytosis). Detailed information on hyperplasia composition is provided in Table 2.
Fig. 7. Comparison of protein profiles from three benign hyperplasia types. Protein profiles were generated from laser micro dissected cells
from reactive hyperplasia types often seen in benign lymph nodes: sinus histiocytosis (upper spectrum), paracortical hyperplasia (predominantly
T-cells) (middle spectrum), and follicular hyperplasia (mainly B-cells) (lower spectrum). The segment from 7,000–14,000 M/Z is shown here
(Y -axis).
a unique micro-environment. For example, FL has a
cellular micro-environment of T-helper cells and den-
dritic cells, while DLBCL and MCL can harbour many
macrophages. These factors, as well as tumour load are
expected to determine the concentration and the rela-
tive peak intensity for individual classifier peaks and
might influence the supervised classification results,
since intensity thresholds are set for each of the clas-
sifier peaks used. Important to realize is that classi-
fier peaks may derive from both the tumour cells as
well as the stroma or micro-environment, as demon-
strated by a specific protein biomarker for pancreatic
duct carcinoma that most likely is derived from the
benign adjacent acini and not from the carcinoma it-
self [29].
5. In conclusion
Our study shows that SELDI-TOF MS based protein
profiling of small histological samples without dissec-
tion of tumour cells is feasible. Moreover, differentia-
tion of NHL types and benign lymph nodes through the
generation of a internally validated classification algo-
rithm using differentially expressed peaks was feasible
although larger studies are required for improved clas-
sification results. The identified classifiers may provide
potentially new biomarkers for use in immunohisto-
or cytochemistry. This method is applicable to many
other samples and therefore represents a potential tool
in clinical pathology, especially when only limited tis-
sue is available.
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